President’s Research Fund (PRF)
The President’s Research Fund (PRF) supports projects that have a strong potential for obtaining external funding for SLU investigators. Funds are used to collect preliminary data that will generate new extramural funding.
Specifically, the PRF will:
- Incentivize new research of high scientific quality that is likely to secure extramural funding.
- Support existing research reviewed favorably by the NIH but not yet funded.
The RPC will administer a single PRF cycle for the School of Medicine (SOM) during FY18 (Cycle 15), with a deadline of January 16, 2018, and a start date of April 2, 2018.
The following three types of applications will be considered for funding:
- PRF01 – Single PI application describing a NEW project with high likelihood of extramural funding, preferably through the R01 or U01 mechanisms. Up to $50,000 may be requested for this award.
- PRF02 – Multi-PI application describing a NEW project with high likelihood of extramural funding, preferably through the P01 mechanism. Up to $100,000 may be requested for this award.
- PRF03 – Existing R01 or U01 application, NEW or RENEWAL, that was scored but not funded by the NIH during 2017. Up to $50,000 may be requested for this award.
Guidelines and Application for Cycle 15:
- Cycle 15 Guidelines: PRF Guidelines
- Cycle 15 Application: PRF Application
- Cycle 15 Subrecipient Form: PRF Subrecipient
Applicants should include a cover letter that justifies submission of the PRF01 or PRF02 as a NEW research project. For PRF03 grants, applicants should include a copy of the original R01 or U01 grant proposal reviewed by the NIH, a copy of the summary statement, and a description, not to exceed 5 pages, of how criticisms raised by the NIH Study Section will be addressed in a revised application.
The application deadline is January 16, 2018 and no late applications will be considered. Applications must be submitted online through eRS as an Internal Proposal. Proposals must be electronically signed by the PI’s department-appointed approver by 5:00 p.m. CST.
All applications (PRF01s, PRF02s and PRF03s) will be reviewed by an Internal Study Section appointed by the RPC and chaired by the current chair of the RPC. Recommendations about funding and amounts to be awarded rest entirely with the Internal Study Section and will be based on scientific merit and likelihood of extramural funding. These recommendations will be forwarded to the Vice President of Research for final approval.
Questions about Cycle 15 of the PRF in the SOM should be directed to Denise Johnson (977-8067; firstname.lastname@example.org).
Example of a successful PRF application: Tavis PRF
Award recipients for the 2018 Cycle 15 applications are listed below.
|Soumya Chatterjee, Mh.D.||IM-Infectious Diseases, Allergy & Immunology||“Efficacy of risk-targeted video based directly on observed therapy for latent TB”|
|Anping Chen, Ph.D.||Pathology||“Mechanisms of the coordination of perilipin 5 and liver fatty acid binding protein in restoring the formation of lipid droplets in hepatic stellate cells”|
|Govindaswamy Chinnadurai, Ph.D.||Molecular Virology||“Probing the mechanism of CtBP1-mutated neurodevelopmental disorder in cell and animal models”|
|Richard DiPaolo, Ph.D.||Molecular Microbiology and Immunology||“IL-13 and gastric cancer”|
|Dale Dorsett, Ph.D.||Biochemistry and Molecular Biology||“Brca2: Non-canonical roles in sister chromatid cohesion and gene regulation”|
|Robert Fleming, M.D.||Pediatrics||“Iron restriction as a therapeutic approach to sickle cell anemia”|
|David Greenberg, M.D.||Orthopaedic Surgery||“Local bisphosphonate effect on recurrence rate in giant cell tumor of bone: A randomized controlled trial”|
|Oleg Kisselev, Ph.D.||Ophthalmology||“Structure-based model of G-protein activation”|
|Daniela Salvemini, Ph.D.||Pharmacological and Physiological Science||“Identification of GPR160 as a novel target for therapeutic intervention in neuropathic pain states”|
|Karoly Toth, D.V.M.||Molecular Microbiology and Immunology||“Identifying host determinants of resistance to oral infection with mouse norovirus”|